Table 2 Quality of included systematic reviews (AMSTAR)
From: Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Review ID AMSTAR Questions | Galling et al. 2016 [32] | Young et al. 2015 [25] | Tranulis et al. 2008 [26] | Tracy et al. 2013 [27] | Anonymous 2012 | Zheng et al. 2016 [24] | Mizuno et al. 2014 [29] | Lerner et al. 2004 [31] | Srisurapanont et al. 2015 [28] | Gallego et al. 2012 [33] | Lochmann van Bennekom et al. 2013 [30] | Correll et al. 2013 [34] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Was an ‘a priori’ design provided? | N | N | N | Y | Y | Y | Y | N | U | N | N | U |
Was there duplicate study selection and data extraction? | N | N | N | N | Y | N | Y | N | N | N | N | U |
Was a comprehensive literature search performed? | N | N | N | Y | Y | Y | Y | N | Y | N | N | U |
Was the status of publication (i.e. grey literature) used as an inclusion criterion? | N | N | N | Y | Y | N | Y | N | Y | N | N | U |
Was a list of studies (included and excluded) provided? | N | N | N | N | N | N | N | N | N | N | N | U |
Were the characteristics of the included studies provided? | Y | N | N | Y | N | Y | Y | Y | Y | N | N | U |
Was the scientific quality of the included studies assessed and documented? | N | Y | N | N | Y | Y | U | N | Y | N | N | U |
Was the scientific quality of the included studies used appropriately in formulating conclusions? | N | N | N | N | Y | Y | Y | N | Y | N | N | U |
Were the methods used to combine the findings of studies appropriate? | Y | N | N/A | N/A | Y | Y | Y | N/A | Y | N/A | N/A | U |
Was the likelihood of publication bias assessed? | Y | N | N | N | N | Y | Y | N | Y | N | N | U |
Was the conflict of interest included? | N | N | N | N | N | N | N | N | N | N | N | U |